Method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value -33.60% · OPTIONAL
· Pharmaceutical Preparations
RESEARCH SNAPSHOTTheravance Biopharma, Inc.'s latest supported as-filed period reports revenue of $20.7M, 20.9% below the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value -33.60% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value -20.86% · CORE
Level · gp.fundamentals.operating_margin
Raw value -39.93% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 22.73% · OPTIONAL
Level · gp.fundamentals.sbc_revenue_ratio
Raw value 28.89% · OPTIONAL
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 2 independently calculated changes: Cash & equivalents decreased 22.0%; Operating cash flow changed across a sign change.
2 evidence-backed componentsThis cluster groups 2 independently calculated changes: Shares outstanding increased 3.1%; SBC / revenue moved 1155 bp higher.
2 evidence-backed componentsCurrent liabilities changed -43.7% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes. This reverses 4 consecutive comparable moves in the opposite direction.
Each point keeps the date investors could first observe it and its accession.
TBPH · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001104659-26-106567SEC ↗8-KAug 25, 2026Period Aug 25, 20260001104659-26-100860SEC ↗4Aug 24, 2026Period Aug 20, 20260001302443-26-000012SEC ↗4Aug 24, 2026Period Aug 20, 20260001961289-26-000008SEC ↗4Aug 24, 2026Period Aug 20, 20260002012524-26-000008SEC ↗4Aug 24, 2026Period Aug 20, 20260001966698-26-000008SEC ↗4Aug 24, 2026Period Aug 20, 20260001898490-26-000012SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Aug 20, 2026Filed Aug 24, 2026 | Winningham Rick ECHIEF EXECUTIVE OFFICER | Tax WithholdingDirect | 20,034 | $17 | $339,576 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Operating income changed -203.7% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Operating margin changed -2952 basis points from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Operating cash flow changed -103.3% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes. Relative percentage is de-emphasized because the comparison has a sign change. This reverses 4 consecutive comparable moves in the opposite direction.
Research & development changed -55.1% from the comparable as-filed period.
Revenue changed -20.9% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
SBC / revenue changed +1155 basis points from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001104659-26-093773